BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$10.76

Market cap

$2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$2.21B

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...

Highlights

Biocryst Pharmaceuticals's quick ratio has surged by 129% YoY and by 14% QoQ

Biocryst Pharmaceuticals's gross margin has increased by 29% YoY and by 3.9% QoQ

BCRX's EPS is up by 11% YoY but it is down by 3.9% from the previous quarter

The net income has increased by 7% year-on-year but it has declined by 5% since the previous quarter

BCRX's equity has dropped by 119% year-on-year and by 53% since the previous quarter

BCRX's debt has soared by 112% YoY and by 3.3% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.biocryst.com

Peers: RGEN SRPT NVAX CLDX

Key stats

What are the main financial stats of BCRX

Market

Shares outstanding

185.58M

Market cap

$2B

Enterprise value

$2.21B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

10.58

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

11.76

Earnings

Revenue

$188.03M

EBIT

-$121.18M

EBITDA

-$120.26M

Free cash flow

-$161.64M

Per share

EPS

-$1.07

Free cash flow per share

-$0.87

Book value per share

-$0.89

Revenue per share

$1.02

TBVPS

$2.85

Balance sheet

Total assets

$527.72M

Total liabilities

$691.94M

Debt

$613M

Equity

-$164.22M

Working capital

$430.7M

Liquidity

Debt to equity

-3.73

Current ratio

6.32

Quick ratio

5.96

Net debt/EBITDA

-1.78

Margins

EBITDA margin

-64%

Gross margin

99.1%

Net margin

-103.2%

Operating margin

-93.8%

Efficiency

Return on assets

-46.8%

Return on equity

N/A

Return on invested capital

-28.3%

Return on capital employed

-27.1%

Return on sales

-64.4%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time

Intraday

5.8%

1 week

11.85%

1 month

25.55%

1 year

-36.71%

YTD

-22.31%

QTD

-33.83%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time

Revenue

$188.03M

Gross profit

$186.42M

Operating income

-$176.3M

Net income

-$193.97M

Gross margin

99.1%

Net margin

-103.2%

The operating margin has soared by 84% YoY and by 17% from the previous quarter

BCRX's net margin has soared by 84% YoY and by 12% QoQ

Biocryst Pharmaceuticals's gross margin has increased by 29% YoY and by 3.9% QoQ

Biocryst Pharmaceuticals's gross profit has increased by 24% from the previous quarter

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation

P/E

N/A

P/B

N/A

P/S

10.58

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

11.76

BCRX's EPS is up by 11% YoY but it is down by 3.9% from the previous quarter

BCRX's equity has dropped by 119% year-on-year and by 53% since the previous quarter

The P/S is 60% lower than the 5-year quarterly average of 26.4 and 53% lower than the last 4 quarters average of 22.5

BCRX's revenue is up by 20% QoQ

Efficiency

How efficient is Biocryst Pharmaceuticals business performance

BCRX's ROS has soared by 88% YoY and by 17% from the previous quarter

The ROIC has soared by 78% YoY and by 25% QoQ

The company's return on assets rose by 44% YoY and by 10% QoQ

Dividends

What is BCRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time

Biocryst Pharmaceuticals's total assets is 24% lower than its total liabilities

Biocryst Pharmaceuticals's current ratio has soared by 133% YoY and by 16% from the previous quarter

Biocryst Pharmaceuticals's quick ratio has surged by 129% YoY and by 14% QoQ

BCRX's equity has dropped by 119% year-on-year and by 53% since the previous quarter

BCRX's debt has soared by 112% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.